## DXCM: DexCom, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.4% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($61.93)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bearish (Bullish: 0, Bearish: 10)

**1. DXCM DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages DexCom, Inc. Investors to Secure Counsel Before Important December 29 Deadline in Securities Class Action – DXCM**
- Source: GlobeNewswire | 20251216T190840 | Bearish | Relevance: 100%
- The Rosen Law Firm is reminding purchasers of DexCom, Inc. securities between July 26, 2024, and September 17, 2025, about the December 29, 2025, lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that DexCom made false and misleading statements about unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which rendered them less reliable and posed health risks. Investors who purchased during this period may be entitled to compensation and are encouraged to contact the law firm.

**2. Portnoy Law Firm Announces Class Action on Behalf of DexCom, Inc. Investors**
- Source: GlobeNewswire | 20251216T140813 | Bearish | Relevance: 100%
- The Portnoy Law Firm has announced a class action lawsuit on behalf of investors in DexCom, Inc. (NASDAQ: DXCM) who purchased securities between July 26, 2024, and September 17, 2025. The lawsuit alleges that DexCom made materially false and misleading statements regarding unauthorized design changes to its G6 and G7 devices, rendering them less reliable and posing health risks, which consequently exposed the company to increased regulatory scrutiny and financial harm. Investors have until December 26, 2025, to file a lead plaintiff motion.

**3. Portnoy Law Firm Announces Class Action on Behalf of DexCom, Inc. Investors**
- Source: GlobeNewswire | 20251216T140229 | Bearish | Relevance: 100%
- The Portnoy Law Firm has announced a class action lawsuit on behalf of DexCom, Inc. investors who purchased securities between July 26, 2024, and September 17, 2025. The lawsuit alleges that DexCom made materially false and misleading statements regarding unauthorized design changes to its G6 and G7 devices, which purportedly rendered them less reliable and posed health risks. Investors have until December 26, 2025, to file a lead plaintiff motion.

**4. DXCM Deadline: DXCM Investors with Losses in Excess of $100K Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit**
- Source: Morningstar | 20251215T221654 | Bearish | Relevance: 100%
- Rosen Law Firm is reminding investors of DexCom, Inc. (NASDAQ: DXCM) who purchased securities between July 26, 2024, and September 17, 2025, of the upcoming December 29, 2025, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that DexCom made unauthorized material design changes to its G6 and G7 continuous glucose monitoring systems and overstated their reliability, leading to potential health risks and increased regulatory scrutiny. Investors with losses exceeding $100K are encouraged to contact the law firm to join the class action.

**5. Lost Money on DexCom, Inc.(DXCM)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky**
- Source: WLNS 6 News | 20251215T210820 | Bearish | Relevance: 100%
- Levi & Korsinsky, LLP has filed a class action securities lawsuit against DexCom, Inc. (NASDAQ: DXCM) on behalf of investors who allegedly suffered losses due to securities fraud between January 8, 2024, and September 17, 2025. The lawsuit claims DexCom made unauthorized material design changes to its G6 and G7 glucose monitoring products, rendering them less reliable and posing health risks, which the company allegedly downplayed. Investors have until December 26, 2025, to request to be appointed lead plaintiff.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Citigroup | $77 | $75 | +3% |
| 2025-12-02 | Morgan Stanley | $75 | $63 | +19% |
| 2025-11-25 | Evercore ISI Gr | $68 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Citigroup | main | Buy |
| 2025-12-02 | Morgan Stanley | up | Overweight |
| 2025-11-25 | Evercore ISI Gr | init | In-Line |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.14M) |
| Sells | 3 ($0.45M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 61.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Tudor Investment Cor: 17.7% (+100.0%)
- Vanguard Group Inc: 12.7% (+2.4%)
- Blackrock Inc.: 10.0% (-0.5%)
- State Street Corpora: 4.3% (-0.0%)
- BAILLIE GIFFORD & CO: 4.1% (-4.9%)

### Key Risks

1. Long-term trend broken: trading 10.7% below SMA200.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.91 indicates undervaluation relative to growth. Quality metrics strong (ROE 31%, margin 16%). Analyst sentiment positive (2 raises, avg +11%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $26.0B |
| Beta | 1.51 |
| 52W Range | $54.11 - $93.25 |
| Short Interest | 4.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.91 |
| Forward P/E | 26.8 |
| Current P/E | 32.1 |
| YoY Growth | 20.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 3.2% to 1.4% (-1.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.6pp (needs >3.0% for momentum thesis). MRS_5 (-0.2%) diverging from MRS_10 - short-term weakness emerging. Below SMA200 (0.89x), long-term trend not supportive. RSI neutral at 57. OFD pattern: +DBN (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.45% (CS: 56) | Neutral |
| RSI_14 | 56.8 | Neutral |
| MACD Histogram | 0.44 | Bullish |
| vs SMA20 | 1.037x | Above |
| vs SMA50 | 1.036x | Above |
| vs SMA200 | 0.893x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $66.37
- **Stop Loss:** $61.93 (6.7% risk)
- **Target:** $70.81 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 225
- **Position Value:** $14,933.25
- **Portfolio %:** 14.93%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-02-12 (Est: $0.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.57 | $0.61 | +7.5% |
| 2025Q2 | $0.44 | $0.48 | +8.2% |
| 2025Q1 | $0.33 | $0.32 | -2.6% |
| 2024Q4 | $0.50 | $0.45 | -9.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*